Carlumab

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameCarlumab
Drug Alias NameCNTO-888
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionC-C motif chemokine 2 inhibitors
TargetsC-C motif chemokine 2
Therapy Area/IndicationsProstatic NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesRussian Federation +[5] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMorphosys Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCentocor Research & Development IncCentocor Inc
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A